Deerfield Management Company, L.P.. (series C) 13F annual report

Deerfield Management Company, L.P.. (series C) is an investment fund managing more than $3.09 trillion ran by Flynn Flynn. There are currently 66 companies in Mr. Flynn’s portfolio. The largest investments include Nuvalent Inc and Viatris, together worth $1.11 trillion.

$3.09 trillion Assets Under Management (AUM)

As of 7th November 2023, Deerfield Management Company, L.P.. (series C)’s top holding is 19,991,024 shares of Nuvalent Inc currently worth over $919 billion and making up 29.8% of the portfolio value. In addition, the fund holds 19,863,485 shares of Viatris worth $196 billion, whose value fell approximately 0.1% in the past six months. The third-largest holding is Centene worth $137 billion and the next is Neurocrine Biosciences worth $136 billion, with 1,209,714 shares owned.

Currently, Deerfield Management Company, L.P.. (series C)'s portfolio is worth at least $3.09 trillion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Deerfield Management Company, L.P.. (series C)

The Deerfield Management Company, L.P.. (series C) office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Flynn Flynn serves as the Managing Member at Deerfield Management Company, L.P.. (series C).

Recent trades

In the most recent 13F filing, Deerfield Management Company, L.P.. (series C) revealed that it had opened a new position in Owens & Minor and bought 6,435,000 shares worth $104 billion. This means they effectively own approximately 0.1% of the company. Owens & Minor makes up 7.5% of the fund's Health Care sector allocation and has decreased its share price by 14.1% in the past year.

The investment fund also strengthened its position in Nuvalent Inc by buying 650,000 additional shares. This makes their stake in Nuvalent Inc total 19,991,024 shares worth $919 billion.

On the other hand, there are companies that Deerfield Management Company, L.P.. (series C) is getting rid of from its portfolio. Deerfield Management Company, L.P.. (series C) closed its position in Sarepta Therapeutics Inc on 14th November 2023. It sold the previously owned 88,657,000 shares for $112 million. Flynn Flynn also disclosed a decreased stake in Viatris by approximately 0.1%. This leaves the value of the investment at $196 billion and 19,863,485 shares.

One of the largest hedge funds

The two most similar investment funds to Deerfield Management Company, L.P.. (series C) are Sumitomo Mitsui Financial Group, Inc and Millburn Ridgefield Corp. They manage $3.09 trillion and $3.08 trillion respectively.


Flynn Flynn investment strategy

Deerfield Management Company, L.P.. (series C)’s portfolio is diversified across 3 sectors. Currently, their heaviest sector is Health Care — making up 44.7% of the total portfolio value. The fund focuses on investments in the United States as 45.5% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 8% of the total holdings value. On the other hand, large-cap stocks make up only 6.1% of the portfolio. The average market cap of the portfolio companies is close to $3.72 billion.

The complete list of Deerfield Management Company, L.P.. (series C) trades based on 13F SEC filings

These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Nuvalent Inc
3.36%
19,991,024
$918,987,373,000 29.77%
Viatris Inc.
3.92%
19,863,485
$195,853,962,000 6.34%
Centene Corp.
243.81%
1,990,000
$137,071,200,000 4.44%
Neurocrine Biosciences, Inc.
39.90%
1,209,714
$136,092,825,000 4.41%
AdaptHealth Corp.
22.04%
13,607,940
$123,832,254,000 4.01%
Owens & Minor, Inc.
Opened
6,435,000
$103,989,600,000 3.37%
Catalyst Pharmaceuticals Inc
Opened
8,192,000
$95,764,480,000 3.10%
Merus N.V
95.22%
3,876,938
$91,418,198,000 2.96%
Deciphera Pharmaceuticals In
10.34%
6,897,606
$87,737,548,000 2.84%
Larimar Therapeutics, Inc.
190.58%
16,941,357
$66,918,360,000 2.17%
Bio Rad Labs Inc
Opened
173,947
$62,351,302,000 2.02%
IDEAYA Biosciences, Inc.
Opened
2,268,628
$61,207,583,000 1.98%
Enhabit, Inc.
Opened
4,997,746
$56,224,643,000 1.82%
Hillevax Inc
52.95%
4,004,231
$53,856,907,000 1.74%
Brookdale Sr Living Inc
47.57%
12,679,651
$52,493,755,000 1.70%
Revolution Medicines Inc
96.45%
1,751,496
$48,481,409,000 1.57%
Integra Lifesciences Hldgs C
Opened
1,126,827
$43,033,523,000 1.39%
Surgery Partners Inc
Opened
1,460,000
$42,705,000,000 1.38%
Ars Pharmaceuticals Inc
Opened
11,077,927
$41,874,564,000 1.36%
Kura Oncology Inc
66.50%
4,374,044
$39,891,281,000 1.29%
Guardant Health Inc
Opened
1,329,935
$39,419,273,000 1.28%
Intercept Pharmaceuticals In
Opened
2,077,893
$38,524,136,000 1.25%
SpringWorks Therapeutics, Inc.
Opened
1,579,574
$36,519,751,000 1.18%
Cabaletta Bio Inc
404.06%
2,340,118
$35,616,596,000 1.15%
Caremax Inc
0.08%
15,873,213
$33,651,212,000 1.09%
Structure Therapeutics Inc
Opened
627,813
$31,654,331,000 1.03%
Rayzebio Inc
Opened
1,159,126
$25,732,597,000 0.83%
Docgo Inc
Opened
4,764,000
$25,392,120,000 0.82%
Biocryst Pharmaceuticals Inc.
Opened
3,286,000
$23,264,880,000 0.75%
Edgewise Therapeutics Inc
No change
3,933,137
$22,536,875,000 0.73%
Insulet Corporation
Opened
127,000
$20,255,230,000 0.66%
Disc Medicine Inc
Opened
430,000
$20,201,400,000 0.65%
Alignment Healthcare Inc
Opened
2,747,015
$19,064,284,000 0.62%
Roivant Sciences Ltd
Opened
1,604,487
$18,740,408,000 0.61%
Caribou Biosciences Inc
Opened
3,500,000
$16,730,000,000 0.54%
Castle Biosciences, Inc.
Opened
946,620
$15,988,412,000 0.52%
Day One Biopharmaceuticals I
63.84%
1,269,992
$15,582,802,000 0.50%
Viking Therapeutics Inc
Opened
1,279,000
$14,158,530,000 0.46%
Tarsus Pharmaceuticals, Inc.
43.06%
754,042
$13,399,326,000 0.43%
Verastem Inc
Opened
1,538,461
$12,507,688,000 0.41%
Denali Therapeutics Inc
Opened
594,989
$12,274,623,000 0.40%
QuidelOrtho Corporation
Opened
150,000
$10,956,000,000 0.35%
Cogent Biosciences, Inc.
81.46%
1,089,345
$10,621,114,000 0.34%
Pulmonx Corp
70.63%
1,017,958
$10,515,506,000 0.34%
Revance Therapeutics Inc
Opened
870,000
$9,978,900,000 0.32%
Vigil Neuroscience Inc
Opened
1,827,400
$9,849,686,000 0.32%
Bicycle Therapeutics plc
Opened
448,753
$9,015,448,000 0.29%
Tango Therapeutics Inc
Opened
793,729
$8,937,389,000 0.29%
Prime Medicine Inc
Opened
885,314
$8,445,896,000 0.27%
4d Molecular Therapeutics In
Opened
650,000
$8,274,500,000 0.27%
iTeos Therapeutics, Inc.
Opened
723,000
$7,916,850,000 0.26%
Fusion Pharmaceuticals Inc.
Opened
2,823,000
$7,339,800,000 0.24%
Alector, Inc.
No change
1,055,192
$6,837,644,000 0.22%
The Oncology Institute Inc
0.68%
3,360,052
$4,704,073,000 0.15%
Genedx Holdings Corp
Opened
1,253,895
$4,564,178,000 0.15%
Foghorn Therapeutics Inc.
No change
777,525
$3,887,625,000 0.13%
Nyxoah S A
12.08%
400,256
$2,821,805,000 0.09%
Black Diamond Therapeutics I
Opened
930,447
$2,670,383,000 0.09%
Orchard Therapeutics plc
Opened
316,169
$2,443,986,000 0.08%
Singular Genomics Systems In
21.33%
4,984,871
$1,899,236,000 0.06%
Acutus Med Inc
0.47%
2,660,808
$1,853,519,000 0.06%
Annexon Inc
No change
583,913
$1,378,035,000 0.04%
Cutera Inc
Opened
154,406
$929,524,000 0.03%
Sarepta Therapeutics Inc
Closed
88,657,000
$111,766,000
Medavail Holdings Inc
Opened
16,732
$100,392,000 0.00%
Silk Rd Med Inc
Closed
2,676,891
$97,412,000
Gilead Sciences, Inc.
Closed
1,552,639
$95,969,000
Immunogen, Inc.
Closed
15,020,490
$67,592,000
Mirum Pharmaceuticals Inc
Closed
3,244,434
$63,137,000
IVERIC bio Inc
Closed
5,214,000
$50,159,000
Glaukos Corporation
Closed
1,039,514
$47,215,000
Molina Healthcare Inc
Closed
167,000
$46,695,000
Cytokinetics Inc
Closed
1,160,315
$45,589,000
Evolus Inc
Closed
3,632,751
$42,140,000
Aerie Pharmaceuticals Inc
Closed
4,695,020
$35,213,000
Sientra Inc
Opened
10,000
$27,800,000 0.00%
Pharvaris N V
Closed
1,190,343
$26,307,000
Horizon Therapeutics Pub L
Closed
313,000
$24,965,000
Sema4 Holdings Corp
Closed
18,848,488
$23,749,000
Bellus Health Inc
Closed
2,473,000
$22,851,000
Organogenesis Holdings Inc.
Closed
4,447,740
$21,705,000
Phreesia Inc
Closed
857,115
$21,436,000
Syndax Pharmaceuticals Inc
Closed
1,111,111
$21,378,000
Amedisys Inc.
Closed
199,000
$20,919,000
Insmed Inc
Closed
960,484
$18,941,000
Pacira BioSciences Inc
Closed
292,000
$17,024,000
Alphatec Holdings Inc
Closed
2,420,547
$15,830,000
AnaptysBio Inc
Closed
772,000
$15,672,000
Da32 Life Scnce Tec Acqstn C
Closed
1,600,000
$15,504,000
Inozyme Pharma, Inc.
Closed
2,696,372
$12,862,000
Profound Med Corp
Closed
1,713,797
$12,494,000
Kezar Life Sciences Inc
Closed
1,419,000
$11,735,000
TG Therapeutics Inc
Closed
2,677,500
$11,379,000
Eucrates Biomedical Acqu Cor
Closed
999,999
$9,900,000
Sarissa Capital Acquisitn Co
Closed
999,999
$9,890,000
Medtech Acquisition Corp
Closed
999,999
$9,845,000
Senior Connect Acquisitn Cor
Closed
1,000,000
$9,840,000
Revolution Healthcar Aq Corp
Closed
1,000,000
$9,770,000
Pepgen Inc
Closed
953,626
$9,470,000
Turmeric Acquisition Corp
Closed
750,000
$7,448,000
Nkarta, Inc.
Closed
600,000
$7,392,000
Ignyte Acquisition Corp
Closed
725,000
$7,149,000
Apollo Endosurgery Inc
Closed
1,750,000
$6,388,000
Xilio Therapeutics Inc
Closed
2,078,692
$6,070,000
Outset Med Inc
Closed
400,622
$5,953,000
Graybug Vision, Inc.
Closed
5,281,713
$5,757,000
An2 Therapeutics Inc
Closed
716,538
$5,553,000
Orion Acquisition Corp
Closed
500,000
$4,900,000
Orchard Therapeutics plc
Closed
6,949,416
$4,060,000
Oncorus, Inc.
Closed
3,148,977
$3,968,000
Werewolf Therapeutics Inc
Closed
958,125
$3,919,000
Quantum Si Inc
Closed
1,400,000
$3,248,000
Kinnate Biopharma Inc.
Closed
250,000
$3,153,000
Delcath Sys Inc
Closed
500,000
$1,995,000
89bio Inc
Closed
506,100
$1,630,000
Medavail Holdings Inc
Closed
836,626
$1,280,000
Rhythm Pharmaceuticals Inc.
Closed
291,005
$1,208,000
Windtree Therapeutics, Inc.
Closed
20,148
$8,000
Trisalus Life Sciences Inc
Opened
1
$5,000 0.00%
No transactions found
Showing first 500 out of 119 holdings